Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

ME, Nassif; SL, Windsor; F, Tang; Y, Khariton; M, Husain; SE, Inzucchi; DK, McGuire; B, Pitt; BM, Scirica; B, Austin; MH, Drazner; MW, Fong; MM, Givertz; RA, Gordon; R, Jermyn; SD, Katz; S, Lamba; DE, Lanfear; SJ, LaRue; J, Lindenfeld; M, Malone; K, Margulies; RJ, Mentz; RK, Mutharasan; M, Pursley; G, Umpierrez; M, Kosiborod

doi:10.1161/circulationaha.119.042929

Public

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

Shared by NobleBlocks on Sep 16, 2019 • 12:00 AM UTC

Authors:

Nassif ME

Windsor SL

Tang F

Abstract

Background Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-gl...

Subject

Biomarkers

Heart Failure

Outcomes

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!